Literature DB >> 31556792

Generalized Linear Models for Flexible Parametric Modeling of the Hazard Function.

Benjamin Kearns1, Matt D Stevenson1, Kostas Triantafyllopoulos1, Andrea Manca1,2.   

Abstract

Background. Parametric modeling of survival data is important, and reimbursement decisions may depend on the selected distribution. Accurate predictions require sufficiently flexible models to describe adequately the temporal evolution of the hazard function. A rich class of models is available among the framework of generalized linear models (GLMs) and its extensions, but these models are rarely applied to survival data. This article describes the theoretical properties of these more flexible models and compares their performance to standard survival models in a reproducible case study. Methods. We describe how survival data may be analyzed with GLMs and their extensions: fractional polynomials, spline models, generalized additive models, generalized linear mixed (frailty) models, and dynamic survival models. For each, we provide a comparison of the strengths and limitations of these approaches. For the case study, we compare within-sample fit, the plausibility of extrapolations, and extrapolation performance based on data splitting. Results. Viewing standard survival models as GLMs shows that many impose a restrictive assumption of linearity. For the case study, GLMs provided better within-sample fit and more plausible extrapolations. However, they did not improve extrapolation performance. We also provide guidance to aid in choosing between the different approaches based on GLMs and their extensions. Conclusions. The use of GLMs for parametric survival analysis can outperform standard parametric survival models, although the improvements were modest in our case study. This approach is currently seldom used. We provide guidance on both implementing these models and choosing between them. The reproducible case study will help to increase uptake of these models.

Entities:  

Keywords:  dynamic survival models; fractional polynomials; frailty models; generalized additive models; generalized linear mixed models; splines; survival analysis; time to event

Mesh:

Year:  2019        PMID: 31556792      PMCID: PMC6843612          DOI: 10.1177/0272989X19873661

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  16 in total

1.  Survival models in health economic evaluations: balancing fit and parsimony to improve prediction.

Authors:  Christopher H Jackson; Linda D Sharples; Simon G Thompson
Journal:  Int J Biostat       Date:  2010       Impact factor: 0.968

2.  Selection of important variables and determination of functional form for continuous predictors in multivariable model building.

Authors:  Willi Sauerbrei; Patrick Royston; Harald Binder
Journal:  Stat Med       Date:  2007-12-30       Impact factor: 2.373

3.  Survival analysis and extrapolation modeling of time-to-event clinical trial data for economic evaluation: an alternative approach.

Authors:  Adrian Bagust; Sophie Beale
Journal:  Med Decis Making       Date:  2013-07-30       Impact factor: 2.583

4.  Extrapolation of Survival Data in Cost-effectiveness Analyses: The Need for Causal Clarity.

Authors:  Neil Hawkins; Richard Grieve
Journal:  Med Decis Making       Date:  2017-03-29       Impact factor: 2.583

5.  flexsurv: A Platform for Parametric Survival Modeling in R.

Authors:  Christopher H Jackson
Journal:  J Stat Softw       Date:  2016-05-12       Impact factor: 6.440

6.  A general framework for parametric survival analysis.

Authors:  Michael J Crowther; Paul C Lambert
Journal:  Stat Med       Date:  2014-09-15       Impact factor: 2.373

7.  Cost-effectiveness of screening for ovarian cancer amongst postmenopausal women: a model-based economic evaluation.

Authors:  Ben Kearns; Jim Chilcott; Sophie Whyte; Louise Preston; Susi Sadler
Journal:  BMC Med       Date:  2016-12-06       Impact factor: 8.775

8.  Accounting for uncertainty in health economic decision models by using model averaging.

Authors:  Christopher H Jackson; Simon G Thompson; Linda D Sharples
Journal:  J R Stat Soc Ser A Stat Soc       Date:  2009-04       Impact factor: 2.483

9.  Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation.

Authors:  Eddie Gibson; Ian Koblbauer; Najida Begum; George Dranitsaris; Danny Liew; Phil McEwan; Amir Abbas Tahami Monfared; Yong Yuan; Ariadna Juarez-Garcia; David Tyas; Michael Lees
Journal:  Pharmacoeconomics       Date:  2017-12       Impact factor: 4.981

10.  Extrapolation of Survival Curves from Cancer Trials Using External Information.

Authors:  Patricia Guyot; Anthony E Ades; Matthew Beasley; Béranger Lueza; Jean-Pierre Pignon; Nicky J Welton
Journal:  Med Decis Making       Date:  2016-09-29       Impact factor: 2.583

View more
  6 in total

1.  Comparison of the performances of survival analysis regression models for analysis of conception modes and risk of type-1 diabetes among 1985-2015 Swedish birth cohort.

Authors:  Adeniyi Francis Fagbamigbe; Emma Norrman; Christina Bergh; Ulla-Britt Wennerholm; Max Petzold
Journal:  PLoS One       Date:  2021-06-25       Impact factor: 3.240

2.  How Uncertain is the Survival Extrapolation? A Study of the Impact of Different Parametric Survival Models on Extrapolated Uncertainty About Hazard Functions, Lifetime Mean Survival and Cost Effectiveness.

Authors:  Ben Kearns; John Stevens; Shijie Ren; Alan Brennan
Journal:  Pharmacoeconomics       Date:  2020-02       Impact factor: 4.981

3.  Performance evaluation of survival regression models in analysing Swedish dental implant complication data with frailty.

Authors:  Adeniyi Francis Fagbamigbe; Karolina Karlsson; Jan Derks; Max Petzold
Journal:  PLoS One       Date:  2021-01-07       Impact factor: 3.240

4.  Comparing current and emerging practice models for the extrapolation of survival data: a simulation study and case-study.

Authors:  Benjamin Kearns; Matt D Stevenson; Kostas Triantafyllopoulos; Andrea Manca
Journal:  BMC Med Res Methodol       Date:  2021-11-27       Impact factor: 4.615

5.  Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China.

Authors:  Taihang Shao; Yinan Ren; Mingye Zhao; Wenxi Tang
Journal:  Front Public Health       Date:  2022-08-15

6.  Dynamic and Flexible Survival Models for Extrapolation of Relative Survival: A Case Study and Simulation Study.

Authors:  Benjamin Kearns; Matt D Stevenson; Kostas Triantafyllopoulos; Andrea Manca
Journal:  Med Decis Making       Date:  2022-06-29       Impact factor: 2.749

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.